Matthew A. Firpo, PhD

Research Interests

  • Cancer Biology
  • Cancer Therapeutic Development
  • Inflammation Mediators
  • Ileus
  • Pancreatitis
  • Role of microenvironmental factors on cellular sensitivity to radiation and to chemotherapeutic agents
  • Tumor Markers, Biological
  • Tumor Cells, Cultured
  • Genes, Tumor Suppressor
  • Gene Expression Profiling
  • Angiogenesis Inducing Agents
  • Hydrogels
  • Implants, Experimental
  • Tumor Microenvironment
  • Gene Expression, Microarray
  • Pancreatic Cancer

Languages

  • English

Academic Information

  • Departments: Surgery - Research Associate Professor
  • Divisions: General Surgery
  • Cancer Center Programs: Experimental Therapeutics

Academic Office Information

  • 801-587-9049
  • School of Medicine
    General Surgery
    30 N 1900 E, Room: 207 Wintrobe
    Salt Lake City, UT 84132

Academic Bio

Matthew Firpo, PhD, is a Research Associate Professor in the Department of Surgery at the University of Utah where he directs the Surgery Research Laboratories. He is also a member of the Pancreas Cancer Research Program and the Experimental Therapeutics Program at Huntsman Cancer Institute.

Firpo's cancer research interests focus on improving intervention and detection strategies for pancreatic cancer. In collaboration with multiple cancer investigators, much of Firpo's efforts involve projects designed to investigate the underlying biology of pancreas cancer. The ultimate goal of these projects is to provide supporting justification for subsequent clinical uses.

Firpo earned his PhD in molecular biology from Brown University in 1994. He completed postdoctoral training in the Departments of Human Genetics and Biochemistry at the University of Utah before joining the Department of Surgery in February 2000.

Education History

Type School Degree
Postdoctoral Fellowship University of Utah
Molecular Biology/Biochemistry
Postdoctoral Fellow
Doctoral Training Brown University
Molecular Biology
Ph.D.
Graduate Training University of Montana
Biochemistry
M.S.
Undergraduate University of Montana
Biology/Chemistry
B.A.

Selected Publications

Journal Article

  1. Capello M, Vykoukal JV, Katayama H, Bantis LE, Wang H, Kundnani DL, Aguilar-Bonavides C, Aguilar M, Tripathi SC, Dhillon DS, Momin AA, Peters H, Katz MH, Alvarez H, Bernard V, Ferri-Borgogno S, Brand R, Adler DG, Firpo MA, Mulvihill SJ, Molldrem JJ, Feng Z, Taguchi A, Maitra A, Hanash SM (2019 Jan 16). Exosomes harbor B cell targets in pancreatic adenocarcinoma and exert decoy function against complement-mediated cytotoxicity. Nat Commun, 10(1), 254.
  2. Graham ME, Neal AK, Newberry IC, Firpo MA, Park AH (2019 Jan 1). Conscious Sedation for Pediatric Peritonsillar Abscess: Comparison of Anesthetic Approaches. Otolaryngol Head Neck Surg, 194599818821905.
  3. Swords DS, Mulvihill SJ, Skarda DE, Finlayson SRG, Stoddard GJ, Ott MJ, Firpo MA, Scaife CL (2019 Jan). Hospital-level Variation in Utilization of Surgery for Clinical Stage I-II Pancreatic Adenocarcinoma. Ann Surg, 269(1), 133-142.
  4. Swords DS, Mulvihill SJ, Brooke BS, Skarda DE, Firpo MA, Scaife CL (2018 Dec 11). Disparities in utilization of treatment for clinical stage I-II pancreatic adenocarcinoma by area socioeconomic status and race/ethnicity.LID - S0039-6060(18)30751-7 [pii]LID - 10.1016/j.surg.2018.10.035 [doi]. (Epub ahead of print) Surgery.
  5. Sharib JM, Fonseca AL, Swords DS, Jaradeh K, Bracci PM, Firpo MA, Hatcher S, Scaife CL, Wang H, Kim GE, Mulvihill SJ, Maitra A, Koay EJ, Kirkwood KS (2018 Dec). Surgical overtreatment of pancreatic intraductal papillary mucinous neoplasms: Do the 2017 International Consensus Guidelines improve clinical decision making? Surgery, 164(6), 1178-1184.
  6. Swords DS, Francis SR, Lloyd S, Garrido-Laguna I, Mulvihill SJ, Gruhl JD, Christensen MC, Stoddard GJ, Firpo MA, Scaife CL (2018 Sep 5). Lymph Node Ratio in Pancreatic Adenocarcinoma After Preoperative Chemotherapy vs. Preoperative Chemoradiation and Its Utility in Decisions About Postoperative Chemotherapy.LID - 10.1007/s11605-018-3953-0 [doi]. (Epub ahead of print) J Gastrointest Surg.
  7. Pulsipher A, Davis BM, Smith KA, Ashby S, Qin X, Firpo M, Orlandi RR, Alt JA (2018 Sep). Calgranulin C (S100A12) Is Differentially Expressed in Subtypes of Chronic Rhinosinusitis. Am J Rhinol Allergy, 32(5), 380-387.
  8. Swords DS, Mulvihill SJ, Firpo MA, Scaife CL (2018 Aug 1). Causes of Death and Conditional Survival Estimates of Medium- and Long-term Survivors of Pancreatic Adenocarcinoma. JAMA Oncol, 4(8), 1129-1130.
  9. Young EL, Thompson BA, Neklason DW, Firpo MA, Werner T, Bell R, Berger J, Fraser A, Gammon A, Koptiuch C, Kohlmann WK, Neumayer L, Goldgar DE, Mulvihill SJ, Cannon-Albright LA, Tavtigian SV (2018 Jun 27). Pancreatic cancer as a sentinel for hereditary cancer predisposition. BMC Cancer, 18(1), 697.
  10. Swords DS, Zhang C, Presson AP, Firpo MA, Mulvihill SJ, Scaife CL (2018 Apr). Association of time-to-surgery with outcomes in clinical stage I-II pancreatic adenocarcinoma treated with upfront surgery. Surgery, 163(4), 753-760.
  11. Almishaal AA, Mathur PD, Hillas E, Chen L, Zhang A, Yang J, Wang Y, Yokoyama WM, Firpo MA, Park AH (2017 Aug). Natural killer cells attenuate cytomegalovirus-induced hearing loss in mice. PLoS Pathog, 13(8), e1006599.
  12. Swords DS, Firpo MA, Johnson KM, Boucher KM, Scaife CL, Mulvihill SJ (2017 Jul). Implications of inaccurate clinical nodal staging in pancreatic adenocarcinoma. Surgery, 162(1), 104-111.
  13. Capello M, Bantis LE, Scelo G, Zhao Y, Li P, Dhillon DS, Patel NJ, Kundnani DL, Wang H, Abbruzzese JL, Maitra A, Tempero MA, Brand R, Firpo MA, Mulvihill SJ, Katz MH, Brennan P, Feng Z, Taguchi A, Hanash SM (2017 Apr 1). Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer.LID - 10.1093/jnci/djw266 [doi]. J Natl Cancer Inst, 109(4).
  14. Carraro M, Almishaal A, Hillas E, Firpo M, Park A, Harrison RV (2017 Apr). Cytomegalovirus (CMV) Infection Causes Degeneration of Cochlear Vasculature and Hearing Loss in a Mouse Model. J Assoc Res Otolaryngol, 18(2), 263-273.
  15. Barneck MD, Rhodes NLR, de la Presa M, Allen JP, Poursaid AE, Nourian MM, Firpo MA, Langell JT (2016 Dec). Violet 405-nm light: a novel therapeutic agent against common pathogenic bacteria. J Surg Res, 206(2), 316-324.
  16. Rhodes NL, de la Presa M, Barneck MD, Poursaid A, Firpo MA, Langell JT (2016 Mar). Violet 405 nm light: A novel therapeutic agent against beta-lactam-resistant Escherichia coli. Lasers Surg Med, 48(3), 311-7.
  17. Beal HL, Shea JE, Witt BL, Adler DG, Mulvihill SJ, Downs-Kelly E, Firpo MA, Scaife CL (). Accuracy of diagnosing PDA, neuroendocrine tumors, and IPMN by EUS-FNA at a single institution. J Gastroenterol Hepatol Res, 4(12), 1844-1849.
  18. Rosati A, Basile A, DAuria R, dAvenia M, De Marco M, Falco A, Festa M, Guerriero L, Iorio V, Parente R, Pascale M, Marzullo L, Franco R, Arra C, Barbieri A, Rea D, Menichini G, Hahne M, Bijlsma M, Barcaroli D, Sala G, di Mola FF, di Sebastiano P, Todoric J, Antonucci L, Corvest V, Jawhari A, Firpo MA, Tuveson DA, Capunzo M, Karin M, De Laurenzi V, Turco MC (2015 Nov 2). BAG3 promotes pancreatic ductal adenocarcinoma growth by activating stromal macrophages. Nat Commun, 6, 8695.
  19. Chari ST, Kelly K, Hollingsworth MA, Thayer SP, Ahlquist DA, Andersen DK, Batra SK, Brentnall TA, Canto M, Cleeter DF, Firpo MA, Gambhir SS, Go VL, Hines OJ, Kenner BJ, Klimstra DS, Lerch MM, Levy MJ, Maitra A, Mulvihill SJ, Petersen GM, Rhim AD, Simeone DM, Srivastava S, Tanaka M, Vinik AI, Wong D (2015 Jul). Early detection of sporadic pancreatic cancer: summative review. Pancreas, 44(5), 693-712.
  20. Gu Y, Shea J, Slattum G, Firpo MA, Alexander M, Mulvihill SJ, Golubovskaya VM, Rosenblatt J (2015 Jan 26). Defective apical extrusion signaling contributes to aggressive tumor hallmarks. eLife, 4, e04069.
  21. Wang AS, Lodi A, Rivera LB, Izquierdo-Garcia JL, Firpo MA, Mulvihill SJ, Tempero MA, Bergers G, Ronen SM (2014 Nov). HR-MAS MRS of the pancreas reveals reduced lipid and elevated lactate and taurine associated with early pancreatic cancer. NMR Biomed, 27(11), 1361-70.
  22. Firpo MA, Boucher KM, Mulvihill SJ (2014 Aug 5). Prospects for developing an accurate diagnostic biomarker panel for low prevalence cancers. Theor Biol Med Model, 11(1), 34.
  23. Kendrick ZW, Firpo MA, Repko RC, Scaife CL, Adler DG, Boucher KM, Mulvihill SJ (2014 Jul). Serum IGFBP2 and MSLN as diagnostic and prognostic biomarkers for pancreatic cancer. HPB (Oxford), 16(7), 670-6.
  24. von Figura G, Fukuda A, Roy N, Liku ME, Morris Iv JP, Kim GE, Russ HA, Firpo MA, Mulvihill SJ, Dawson DW, Ferrer J, Mueller WF, Busch A, Hertel KJ, Hebrok M (2014 Mar). The chromatin regulator Brg1 suppresses formation of intraductal papillary mucinous neoplasm and pancreatic ductal adenocarcinoma. Nat Cell Biol, 16(3), 255-67.
  25. Wang Y, Patel R, Ren C, Taggart MG, Firpo MA, Schleiss MR, Park AH (2013 Nov). A comparison of different murine models for cytomegalovirus-induced sensorineural hearing loss. Laryngoscope, 123(11), 2801-6.
  26. Schwartz JJ, Emerson L, Hillas E, Phan A, Thiesset H, Firpo M, Sorensen J, Kennedy T, Rinella M (2013 Jun). Amelioration of hepatic inflammation in a mouse model of NASH using a dithiocarbamate derivative. Hepatol Int, 7(2), 600-9.
  27. Poruk KE, Gay DZ, Brown K, Mulvihill JD, Boucher KM, Scaife CL, Firpo MA, Mulvihill SJ (2013 Mar). The clinical utility of CA 19-9 in pancreatic adenocarcinoma: diagnostic and prognostic updates. Curr Mol Med, 13(3), 340-51.
  28. Poruk KE, Firpo MA, Scaife CL, Adler DG, Emerson LL, Boucher KM, Mulvihill SJ (2013 Mar). Serum osteopontin and tissue inhibitor of metalloproteinase 1 as diagnostic and prognostic biomarkers for pancreatic adenocarcinoma. Pancreas, 42(2), 193-7.
  29. Elia R, Newhide DR, Pedevillano PD, Reiss GR, Firpo MA, Hsu EW, Kaplan DL, Prestwich GD, Peattie RA (2013 Feb). Silk-hyaluronan-based composite hydrogels: a novel, securable vehicle for drug delivery. J Biomater Appl, 27(6), 749-62.
  30. Granger JH, Granger MC, Firpo MA, Mulvihill SJ, Porter MD (2013 Jan 21). Toward development of a surface-enhanced Raman scattering (SERS)-based cancer diagnostic immunoassay panel. Analyst, 138(2), 410-6.
  31. Poruk KE, Firpo MA, Adler DG, Mulvihill SJ (2013 Jan). Screening for pancreatic cancer: why, how, and who? Ann Surg, 257(1), 17-26.
  32. Park AH, Mann D, Error ME, Miller M, Firpo MA, Wang Y, Alder SC, Schleiss MR (2013 Jan). Comparative analysis of detection methods for congenital cytomegalovirus infection in a Guinea pig model. JAMA Otolaryngol Head Neck Surg, 139(1), 82-6.
  33. Jose RR, Elia R, Firpo MA, Kaplan DL, Peattie RA (2012 Nov). Seamless, axially aligned, fiber tubes, meshes, microbundles and gradient biomaterial constructs. J Mater Sci Mater Med, 23(11), 2679-95.
  34. Keefe MD, Wang H, De La O JP, Khan A, Firpo MA, Murtaugh LC (2012 Jul). beta-catenin is selectively required for the expansion and regeneration of mature pancreatic acinar cells in mice. Dis Model Mech, 5(4), 503-14.
  35. Miller CJ, Gounder SS, Kannan S, Goutam K, Muthusamy VR, Firpo MA, Symons JD, Paine R 3rd, Hoidal JR, Rajasekaran NS (2012 Jun). Disruption of Nrf2/ARE signaling impairs antioxidant mechanisms and promotes cell degradation pathways in aged skeletal muscle. Biochim Biophys Acta, 1822(6), 1038-50.
  36. Gounder SS, Kannan S, Devadoss D, Miller CJ, Whitehead KJ, Odelberg SJ, Firpo MA, Paine R 3rd, Hoidal JR, Abel ED, Rajasekaran NS (2012). Impaired transcriptional activity of Nrf2 in age-related myocardial oxidative stress is reversible by moderate exercise training. PLoS ONE, 7(9), e45697.
  37. Fukuda A, Wang SC, Morris JP 4th, Folias AE, Liou A, Kim GE, Akira S, Boucher KM, Firpo MA, Mulvihill SJ, Hebrok M (2011 Apr 12). Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression. Cancer Cell, 19(4), 441-55.
  38. Rajasekaran NS, Varadharaj S, Khanderao GD, Davidson CJ, Kannan S, Firpo MA, Zweier JL, Benjamin IJ (). Sustained activation of nuclear erythroid 2-related factor 2/antioxidant response element signaling promotes reductive stress in the human mutant protein aggregation cardiomyopathy in mice. Antioxid Redox Signal, 14(6), 957-71.
  39. Wilson MA, Orlandi RR, Firpo MA (2011 Mar-Apr). Correlating matrix metalloproteinase-9 sinus secretion levels with tissue biopsy levels. Int Forum Allergy Rhinol, 1(2), 106-8.
  40. Lee M, Martin H, Firpo MA, Demerath EW (2011 Jan-Feb). Inverse association between adiposity and telomere length: The Fels Longitudinal Study. Am J Hum Biol, 23(1), 100-6.
  41. Poruk KE, Firpo MA, Huerter LM, Scaife CL, Emerson LL, Boucher KM, Jones KA, Mulvihill SJ (2010 Oct). Serum platelet factor 4 is an independent predictor of survival and venous thromboembolism in patients with pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev, 19(10), 2605-10.
  42. Scaife CL, Shea J, Emerson L, Boucher K, Firpo MA, Beckerle MC, Mulvihill SJ (2010 Jun). Prognostic significance of PINCH signalling in human pancreatic ductal adenocarcinoma. HPB (Oxford), 12(5), 352-8.
  43. Elia R, Fuegy PW, VanDelden A, Firpo MA, Prestwich GD, Peattie RA (2010 Jun). Stimulation of in vivo angiogenesis by in situ crosslinked, dual growth factor-loaded, glycosaminoglycan hydrogels. Biomaterials, 31(17), 4630-8.
  44. Firpo MA, Gay DZ, Granger SR, Scaife CL, DiSario JA, Boucher KM, Mulvihill SJ (2009 Apr). Improved diagnosis of pancreatic adenocarcinoma using haptoglobin and serum amyloid A in a panel screen. World J Surg, 33(4), 716-22.
  45. Rajasekaran NS, Firpo MA, Milash BA, Weiss RB, Benjamin IJ (2008). Global expression profiling identifies a novel biosignature for protein aggregation R120GCryAB cardiomyopathy in mice. Physiol Genomics, 35(2), 165-72.
  46. Torgenson MJ, Shea JE, Firpo MA, Dai Q, Mulvihill SJ, Scaife CL (2008 Sep). Natural history of pancreatic cancer recurrence following "curative" resection in athymic mice. J Surg Res, 149(1), 57-61.
  47. Peattie RA, Pike DB, Yu B, Cai S, Shu XZ, Prestwich GD, Firpo MA, Fisher RJ (2008). Effect of gelatin on heparin regulation of cytokine release from hyaluronan-based hydrogels. Drug Deliv, 15(6), 389-97.
  48. Scaife CL, Shea JE, Dai Q, Firpo MA, Prestwich GD, Mulvihill SJ (2008). Synthetic extracellular matrix enhances tumor growth and metastasis in an orthotopic mouse model of pancreatic adenocarcinoma. J Gastrointest Surg, 12(6), 1074-80.
  49. Hosack LW, Firpo MA, Scott JA, Prestwich GD, Peattie RA (2008 May). Microvascular maturity elicited in tissue treated with cytokine-loaded hyaluronan-based hydrogels. Biomaterials, 29(15), 2336-47.
  50. Riley CM, Fuegy PW, Firpo MA, Shu XZ, Prestwich GD, Peattie RA (2006 Dec). Stimulation of in vivo angiogenesis using dual growth factor-loaded crosslinked glycosaminoglycan hydrogels. Biomaterials, 27(35), 5935-43.
  51. Pike DB, Cai S, Pomraning KR, Firpo MA, Fisher RJ, Shu XZ, Prestwich GD, Peattie RA (2006 Oct). Heparin-regulated release of growth factors in vitro and angiogenic response in vivo to implanted hyaluronan hydrogels containing VEGF and bFGF. Biomaterials, 27(30), 5242-51.
  52. Rollins MD, Sudarshan S, Firpo MA, Etherington BH, Hart BJ, Jackson HH, Jackson JD, Emerson LL, Yang DT, Mulvihill SJ, Glasgow RE (2006 Sep-Oct). Anti-inflammatory effects of PPAR-gamma agonists directly correlate with PPAR-gamma expression during acute pancreatitis. J Gastrointest Surg, 10(8), 1120-30.
  53. Firpo MA, Rollins MD, Szabo A, Gull JD, Jackson JD, Shao Y, Glasgow RE, Mulvihill SJ (2005 Jun 6). A conscious mouse model of gastric ileus using clinically relevant endpoints. BMC Gastroenterol, 5(1), 18.
  54. Hermanson B, Firpo M, Cochran A, Neumayer L (2004 Nov). Does the National Board of Medical Examiners' Surgery Subtest level the playing field? Am J Surg, 188(5), 520-1.
  55. Peattie RA, Nayate AP, Firpo MA, Shelby J, Fisher RJ, Prestwich GD (2004 Jun). Stimulation of in vivo angiogenesis by cytokine-loaded hyaluronic acid hydrogel implants. Biomaterials, 25(14), 2789-98.
  56. Jackson HH, Jackson JD, Mulvihill SJ, Firpo MA, Glasgow RE (2004 Feb). Trends in research support and productivity in the changing environment of academic surgery. J Surg Res, 116(2), 197-201.
  57. Lieberman KR, Firpo MA, Herr AJ, Nguyenle T, Atkins JF, Gesteland RF, Noller HF (2000 Apr 14). The 23 S rRNA environment of ribosomal protein L9 in the 50 S ribosomal subunit. J Mol Biol, 297(5), 1129-43.
  58. Grentzmann G, Kelly PJ, Laalami S, Shuda M, Firpo MA, Cenatiempo Y, Kaji A (1998 Aug). Release factor RF-3 GTPase activity acts in disassembly of the ribosome termination complex. RNA, 4(8), 973-83.
  59. Firpo MA, Dahlberg AE (1998 May 1). The importance of base pairing in the penultimate stem of Escherichia coli 16S rRNA for ribosomal subunit association. Nucleic Acids Res, 26(9), 2156-60.
  60. Firpo MA, Connelly MB, Goss DJ, Dahlberg AE (1996 Mar 1). Mutations at two invariant nucleotides in the 3'-minor domain of Escherichia coli 16 S rRNA affecting translational initiation and initiation factor 3 function. J Biol Chem, 271(9), 4693-8.

Review

  1. De Marco M, Basile A, Iorio V, Festa M, Falco A, Ranieri B, Pascale M, Sala G, Remondelli P, Capunzo M, Firpo MA, Pezzilli R, Marzullo L, Cavallo P, De Laurenzi V, Turco MC, Rosati A (2018 Jun). Role of BAG3 in cancer progression: A therapeutic opportunity. [Review]. Semin Cell Dev Biol, 78, 85-92.
  2. Swords DS, Firpo MA, Scaife CL, Mulvihill SJ (2016). Biomarkers in pancreatic adenocarcinoma: current perspectives. [Review]. Onco Targets Ther, 9, 7459-7467.
  3. Peattie, RA, Grentzmann, IP, and Firpo, MA (). Recent Advances in Delivery of Cytokines, Growth Factors, and Molecules of Therapeutic Interest from Hyaluronan-based Hydrogels. [Review]. Curr Tissue Eng, 4(1), 47-56.
  4. Deer EL, Gonzalez-Hernandez J, Coursen JD, Shea JE, Ngatia J, Scaife CL, Firpo MA, Mulvihill SJ (2010 May). Phenotype and genotype of pancreatic cancer cell lines. [Review]. Pancreas, 39(4), 425-35.
  5. OConnor M, Brunelli CA, Firpo MA, Gregory ST, Lieberman KR, Lodmell JS, Moine H, Van Ryk DI, Dahlberg AE (1995 Nov-Dec). Genetic probes of ribosomal RNA function. [Review]. Biochem Cell Biol, 73(11-12), 859-68.

Book Chapter

  1. Poruk KE, Firpo MA, Mulvihill SJ (2014). Screening for pancreatic cancer. In Adv Surg (48, pp. 115-36). United States.
  2. Firpo MA, Dahlberg, AE (1990-01-01). The role of ribosomal RNA in the control of gene expression. In In McCarthy, JEG and Tuite, MF (Eds) Post-transcriptional Control of Gene Expression (NATO ASI Series vol 49, pp. 185-195).

Abstract

  1. Taguchi A, Capello M, Zhao Y, Babel I, Goodman G, Tempero MA, Firpo MA, Katz MH, Feng Z, and Hanash S (). Development and validation of diagnostic biomarker model for detection of early stage pancreatic cancer [Abstract]. Cancer Res, 75(13 Suppl), B20.
  2. Kamal S, Firpo MA, Scaife CL, Adler DG, Boucher KM, and Mulvihill SJ (). Plasma Basigin as an Early Detection Biomarker for Pancreatic Adenocarcinoma [Abstract]. Cancer Res, 75(13 Suppl), B23.
  3. Khanderao G, Granger JH, Granger MC, Firpo MA, Porter MD, Mulvihill SJ (). Optimization Method for the Simultaneous Detection of Multiple Pancreatic Cancer Markers using a Surface-enhanced Raman Scattering (SERS) Immunoassay [Abstract]. Pancreas, 43(8), 1377.
  4. Beal HL, Dai Q, Shea JE, Scaife CL, Firpo MA, Mulvihill SJ (). Heterogeneity of pancreatic cancer associated fibroblasts [Abstract]. HPB, 15(Suppl 1), 6.
  5. Repko RC, Kendrick ZW, Firpo MA, Scaife CL Adler DG, Boucher KM, Mulvihill SJ (). Serum IGFBP2 and MSLN as diagnsotic and prognostic biomarkers for pancreatic adenocarcinoma [Abstract]. HPB, 15(Suppl 1), 66.
  6. Kendrick Z W, Firpo MA, Scaife CL, Adler DG, Boucher KM, Mulvihill SJ (). Evaluation of serum mesothelin as a diagnostic and prognostic biomarker for pancreatic adenocarcinoma [Abstract]. HPB, 14(Suppl 1), 39.
  7. Firpo MA, Shea JE, Brown K, Emerson LE, Boucher KM, Scaife CL, Mulvihill SJ (). Serum MMP-7 is an Independent Predictor of Survival in Patients with Pancreatic Adenocarcinoma [Abstract]. HPB, 13(Suppl 1), 21.
  8. Firpo MA, Coursen JD, White BR, Livers GL, Mulvihill SJ (). Rosiglitazone Antagonizes Gemcitabine Activity in Pancreatic Adenocarcinoma via Cell-cycle Arrest [Abstract]. HPB, 13(Suppl 1), 20.
  9. Schwartz J, Firpo M, Hillas H, Takahshi N, Weiss R, Dunn D, Judkins J, Chen X, Clayton F, Canale C, Hutson W, Sorensen J, Rohrwasser A, Kim R, Lalouel J-M (). Hepatic Necrosis-Induced Renal Failure: A Molecular Study [Abstract]. Hepatology International, 5(1), 23.
  10. Schwartz JJ, Hilas E, Firpo MA (). Decrease in Renal Survivin Levels in Acute Liver Failure Parallel the
    Development of Functional Renal Failure
    [Abstract]. Am J Transplant, 10(Suppl 4), 352.
  11. Jennings CS, Coursen JD, Dai Q, Firpo MA, Mulvihill SJ (). Spontaneous Development of Gemcitabine Resistance in Pancreatic Cancer Cell Lines [Abstract]. HPB, 12(Suppl 1), 302.
  12. Scaife C, Firpo M, Emerson L, Shea J, Boucher K, Beckerle M, Mulvihill S (3-28-2008). Prognostic Significance of PINCH Signaling in Human Pancreatic Adenocarcinoma [Abstract]. HPB, 10(1(S1)), 53-54.
  13. Coursen, JD, Covey, TM, Edes, K, Boucher, KM, Firpo, MA, Fitzpatrick, FA, Mulvihill, SJ (4-20-2007). Synergistic Effect of Simultaneous 5-LOX and COX-2 Inhibition on Pancreas Cancer Cell Growth In Vitro [Abstract]. HPB, 9(2 (S1)), 47.
  14. Dai, Q, Firpo, MA, Coursen, JD, Mulvihill, SJ (4-20-2007). Fibroblasts Promote Pancreatic Cancer Cell Growth In Vitro [Abstract]. HPB, 9(2(S1)), 44.
  15. Scaife, CL, Shea, JE, Dai, Q, Lui, Y, Shu, XZ, Firpo, MA, Prestwich, GD, Mulvihill, SJ (3-10-2006). A pilot study of a novel mouse model of human pancreas adenocarcinoma [Abstract]. HPB, 8(1(S1)), 33.
  16. Firpo, MA, Granger, SR, Omer, EN, Disario, JA, Scaife, CL, Mulvihill, SJ (3-1-2006). Diagnostic potential of acute phase proteins in pancreatic adenocarcinoma [Abstract]. HPB, 8(1(S1)), 67.
  17. Dai, Q, Firpo, MA, Coursen, JD, Scaife, CL, Mulvihill, SJ (3-10-2006). Resistance of pancreatic cancer to chemotherapy in vitro is related to tumor-stromal interaction [Abstract]. HPB, 8(1(S1)), 52.
  18. Granger SR, Firpo MA, Kime M, Yang DT, Mulvihill SJ, Benjamin IJ, Glasgow RE (2-8-2006). Development of Cerulein-induced Acute Pancreatitis is Independent of Cross-tolerance after Heat Shock in Mice [Abstract]. J Surg Res, 130(2), 198-199.
  19. Rollins MD, Jackson HH, Emerson LL, Mulvihill SJ, Firpo MA, Glasgow RE (02/18/2003). Peroxisome Proliferator-Activated Receptor-Gamma Agonists Decrease the Severity of Acute Pancreatitis [Abstract]. Journal of Gastrointestinal Surgery, 7(2), 289-290.
  20. Firpo MA, Jackson JD, Rollins MD, Glasgow RE, Mulvihill SJ (02/18/2003). Time Course of Gastric Ileus in a Conscious Mouse Model of Acute Pancreatitis [Abstract]. Journal of Gastrointestinal Surgery, 7(2), 289.

Other

  1. Gounder SS, Kannan S, Devadoss D, Miller CJ, Whitehead KS, Odelberg SJ, Firpo MA, Paine R 3rd, Hoidal JR, Abel ED, Rajasekaran NS (2013). Correction: Impaired Transcriptional Activity of Nrf2 in Age-Related Myocardial Oxidative Stress Is Reversible by Moderate Exercise Training.LID - 10.1371/annotation/684807c2-1777-4008-9eda-c6036553b082 [doi]. Med Image Comput Comput Assist Interv (8(6)).
  2. Gounder SS, Kannan S, Devadoss D, Miller CJ, Whitehead KJ, Odelberg SJ, Firpo MA, Paine R 3rd, Hoidal JR, Abel ED, Rajasekaran NS (2012). Correction: Impaired Transcriptional Activity of Nrf2 in Age-Related Myocardial Oxidative Stress Is Reversible by Moderate Exercise Training.LID - 10.1371/annotation/8690bb36-3c5d-48a6-b3be-39a2b50896e1 [doi]. Information Communication of Immunotoxicology (7(10)).